Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 34

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 34
---
 which has been open since June 2025.

<div align='center'>17</div>

Nasdaq Deficiency

On October 8, 2024, the Company
received a deficiency letter (“Bid Price Deficiency Letter”) from the Listing Qualifications Department (the “Staff”)
of Nasdaq notifying the Company that it is currently not in compliance with the closing bid price requirement under Nasdaq Listing Rule
5450(a)(1) (the “Minimum Bid Price Rule”). The Bid Price Deficiency Letter stated that, for the preceding 30 consecutive business
days, the Company’s Class A Ordinary Shares did not meet the minimum closing bid price of $1 per share pursuant to the Minimum Bid
Price Rule. The Company has an initial compliance period of 180 calendar days, or until April 7, 2025 to regain compliance with the Minimum
Bid Price Rule. The Deficiency letter stated that if at any time the closing bid price of the Company’s Class A Ordinary Shares
is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance with
this requirement, as applicable. On February 11, 2025, the Company effected a 1-for-20 reverse stock split of its issued and unissued
shares. The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025,
the Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company’s securities had been
at $1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the Company had regained
compliance with the Minimum Bid Price Rule.

On May 24, 2024, the Company
received a deficiency letter (“MVLS Deficiency Letter”) from the Staff of Nasdaq notifying the Company that, for the preceding
35 consecutive business days, the Class A Shares did not meet the minimum $50,000,000 Market Value of Listed Securities requirement (“MVLS
Requirement”) for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(A) (the “MVLS Requirement,”
and the Company’s non-compliance with this requirement, the “MVLS Deficiency”). In accordance with Nasdaq Rule 5810(c)(3)(C),
the Company has been provided an initial period of 180 calendar days